3-(1-Ethoxyethoxy)-4-phenylazetidin-2-one
- CAS No.201856-48-6
- GradeIndustrial / Pharmaceutical
- Availability● In Stock
High-purity 3-(1-Ethoxyethoxy)-4-phenylazetidin-2-one serves as a critical chiral intermediate for Paclitaxel synthesis, available in bulk quantities with full documentation.
Request Bulk PricingProduct Technical Details
Product Overview
3-(1-Ethoxyethoxy)-4-phenylazetidin-2-one is a specialized pharmaceutical intermediate characterized by its distinct azetidinone core structure. This compound plays a pivotal role in the complex synthetic pathways required for producing high-value oncology therapeutics. Manufactured under strict quality control protocols, our material ensures consistent stereochemical integrity, specifically targeting the (3R,4S) configuration essential for biological activity in downstream applications. As a leading global manufacturer, we provide this key building block to support the robust production of taxane-based medications.
The chemical structure features a protected hydroxyl group via an ethoxyethoxy moiety, which enhances stability during multi-step synthesis processes. This protection strategy is crucial for maintaining reaction specificity and minimizing side reactions during the assembly of complex molecular architectures. Our production facilities are equipped to handle large-scale demands while adhering to international safety and environmental standards.
Chemical Specifications
| Parameter | Value |
|---|---|
| CAS Number | 201856-48-6 |
| Molecular Formula | C13H17NO3 |
| Molecular Weight | 235.28 g/mol |
| Appearance | White to off-white powder |
| Assay (Purity) | ≥97.0% |
| Density | 1.14 g/cm3 |
| Boiling Point | 399.2°C at 760 mmHg |
| Flash Point | 195.2°C |
Industrial Applications
The primary application of this azetidinone derivative is in the synthesis of Paclitaxel, a widely recognized chemotherapy agent used in the treatment of various cancers including ovarian, breast, and lung cancers. The high optical purity of our intermediate ensures that the final pharmaceutical product meets stringent regulatory requirements for enantiomeric excess. Beyond Paclitaxel, this building block may serve as a versatile precursor for other taxane analogs and novel anti-neoplastic agents currently in development.
- Key intermediate for Paclitaxel side chain construction
- Utilized in stereoselective organic synthesis
- Supports R&D for new taxane derivatives
- Compatible with standard pharmaceutical manufacturing processes
Quality Assurance and Storage
Quality is paramount in pharmaceutical supply chains. Each batch of 3-(1-Ethoxyethoxy)-4-phenylazetidin-2-one undergoes rigorous analytical testing using HPLC, NMR, and mass spectrometry to verify identity and purity. We provide a comprehensive Certificate of Analysis (COA) with every shipment, ensuring full traceability and compliance with customer specifications. Our quality management system is designed to prevent contamination and ensure batch-to-batch consistency.
For optimal stability, the product should be stored in a cool, ventilated area away from direct sunlight and moisture. Standard packaging includes 25 kg drums, though we offer flexible packaging solutions tailored to specific logistical requirements. Proper handling procedures should be followed to maintain the integrity of the material during transport and storage. Contact our technical team for detailed safety data sheets and customization options regarding bulk orders.
